Can these drugs ease long COVID? new trial aims to find out
NCT ID NCT05513560
First seen Feb 26, 2026 · Last updated Jun 20, 2026 · Updated 14 times
Summary
This Canadian trial tested two drugs, ibudilast and pentoxifylline, against a placebo in 460 adults with lingering COVID-19 symptoms. Participants took the drugs for 2 months and were followed for 4 more months to see if symptoms improved. The goal is to find safe, effective treatments for long COVID.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mount Sinai Hospital
Toronto, Ontario, Canada
-
The Ottawa Hospital
Ottawa, Ontario, Canada
-
University Health Network, Osteoporosis Department
Toronto, Ontario, M5G 2C4, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ibudilast and pentoxifylline
What this could lead to
If successful, this could point toward effective treatments to reduce long COVID symptoms and improve daily functioning.
What could go wrong
This is an early adaptive trial with no confirmed results yet. The drugs may not work better than placebo, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.